DaVita (DVA) Set to Announce Quarterly Earnings on Thursday

Key Points

• DaVita is scheduled to report Q3 2026 earnings after market close on October 29. Analysts expect $3.57 in earnings per share and $3.52 billion in revenue; the company’s full-year EPS guidance is $14.10–$15.20.
• In its most recent quarter, DaVita earned $4.02 per share, beating consensus by $0.14, while revenue rose 5.2% year over year to $3.55 billion.
• Analyst sentiment is moderately bullish, with four Buy and three Hold ratings and a consensus price target of $233.43, compared with the stock’s opening price of $176.65.

DaVita (NYSE:DVA - Get Free Report) is expected to issue its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of $3.57 per share and revenue of $3.52 billion for the quarter. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Parties may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same period last year, the business earned $2.95 EPS. The firm's revenue was up 5.2% compared to the same quarter last year. On average, analysts expect DaVita to post $14.57 EPS for the current fiscal year and $17.25 EPS for the next fiscal year.

DaVita Stock Performance

DVA opened at $176.65 on Thursday. The business has a 50 day moving average price of $180.38 and a 200 day moving average price of $191.46. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The firm has a market cap of $11.27 billion, a P/E ratio of 14.46, a price-to-earnings-growth ratio of 0.45 and a beta of 0.80.

Analyst Ratings Changes

Several brokerages have commented on DVA. TD Cowen reiterated a "buy" rating on shares of DaVita in a report on Wednesday. Weiss Ratings upgraded shares of DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, October 9th. UBS Group upped their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $265.00 price objective on shares of DaVita in a report on Wednesday, August 5th. Finally, Barclays raised their target price on shares of DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $233.43.

About DaVita

DaVita Inc NYSE: DVA is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.